JPM moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as Thermo Fisher's potential acquisition of Qiagen played out.
The commercial labs will also receive testing equipment from Beckman Coulter Life Sciences and Thermo Fisher Scientific including RT-PCR instrumentation.
Qiagen shareholders tendered only 47 percent of the firm's issued and outstanding shares by Monday's deadline, short of the two-thirds minimum needed to complete the deal.
Cities and start-ups are pushing to incorporate SARS-CoV-2 wastewater monitoring into pandemic responses even as basic science researchers scramble to hammer out methods.
The firm saw revenues grow 10 percent in Q2, in part driven by PCR-based COVID-19 testing, as it increased production capacity to 10 million tests per week.
